Article

Interim results from comparison of immune responses elicited by an inactivated and a vectored SARS-CoV-2 vaccine in seronegative and seropositive participants in India

2023-01-05

Abstract excerpt

<h4>Background</h4> There are limited global data on head-to-head comparisons of vaccine platforms assessing both humoral and cellular immune responses, stratified by pre-vaccination serostatus. The COVID-19 vaccination drive for the Indian population in the 18 to 45-year age-group began in April 2021 when seropositivity rates in the general population were rising due to the Delta wave in April-May 2021. <h4>Metho...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fb7e2d55-3790-5dee-9c81-d6ca7dcc1f67
DOI: 10.1101/2023.01.03.22284082

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Interim results from comparison of immune responses elicited by an inactivated and a vectored SARS-CoV-2 vaccine in seronegative and seropositive participants in IndiaDOI 10.1101/2023.01.03.22284082Read

Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), IndiaSemantic proximity Read

Prevalence of Igg Antibodies Against SARS-CoV-2 Among the General Population and Healthcare Workers in India, June–July 2021Semantic proximity Read

SARS-CoV-2 seroprevalence in Delhi, India - September-October 2021 – a population based seroepidemiological studySemantic proximity Read

SARS-CoV2 Wild-type and Delta VOC infection dynamics in a Paediatric cohort in India (South)Semantic proximity Read

Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical TrialSemantic proximity Read

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and diseaseSemantic proximity Read

Comparing COVID-19 vaccine allocation strategies in India: a mathematical modelling studySemantic proximity Read

Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in EnglandSemantic proximity Read

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineSemantic proximity Read

Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccinationSemantic proximity Read

Vaccine-induced and hybrid immunity against SARS-CoV-2 variants of concern in two cohorts in Queensland, Australia (2021-2022)Semantic proximity Read

Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity Read